Risperidone plasma concentrations are associated with side effects and effectiveness in children and adolescents with autism spectrum disorder

The results of this study (n=42; 6-18 years) suggest that a therapeutic window exists for effectiveness of risperidone in this population with acceptable weight gain, and therefore that therapeutic drug monitoring may increase its safety and efficacy. Further research is needed

British Journal of Clinical Pharmacology